Previous 10 | Next 10 |
home / stock / kaltf / kaltf news
SAN FRANCISCO and TORONTO, July 26, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that a recently published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust ...
SAN FRANCISCO and TORONTO, July 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") is pleased to provide additional detail regarding exceptionally positive data with R-107 in a validated animal model of pu...
SAN FRANCISCO, July 20, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") is pleased to announce that the previously disclosed consolidation of its Common Shares (the " Consolidation ") has recei...
SAN FRANCISCO and TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced that it has received commitments from the Company’s two l...
SAN FRANCISCO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has entered into an agreement (the “Debt Forgiveness Agreement” ) with ...
SAN FRANCISCO and TORONTO, May 11, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE (TSXV): CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today issued the following letter to shareholders from Robert Farrell, the Comp...
Claritas Pharmaceuticals ([[KALTF]] +16.1%) has entered into an agreement with CMAX Clinical Research to conduct a randomized, placebo-controlled, single-blind, single ascending dose Phase 1 clinical study to evaluate the pharmacokinetics and safety profile of R-107.The study is expected to b...
SAN FRANCISCO and TORONTO, April 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has entered into an agreement with CMAX Clinical Research Pty Ltd ( “CMAX” ) to...
SAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has entered into a binding Letter of Intent (the “LOI” ) with Salzman Group, In...
SAN FRANCISCO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that, based on significantly positive results in a controlled large animal model of sepsis...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...